Guan Wang

发表

Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia

J. Taub, Tristan E. Knight, Fangbing Liu, 2019, Signal Transduction and Targeted Therapy.

Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer

Shuang Liu, Lijing Zhao, Yang Dong, 2021, Cancer Chemotherapy and Pharmacology.

Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells

J. T. Caldwell, J. Taub, S. Buck, 2013, PloS one.

Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer.

Hebin Wang, Lijing Zhao, Guan Wang, 2014, Cancer letters.

c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia

J. Taub, Hai Lin, H. Edwards, 2022, Apoptosis.

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

G. Madlambayan, J. Taub, Tristan E. Knight, 2020, Haematologica.

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

J. Taub, H. Edwards, Guan Wang, 2022, Cells.

Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia

Hai Lin, H. Edwards, Guan Wang, 2022, Journal of cellular and molecular medicine.

Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells

J. Taub, H. Edwards, Guan Wang, 2016, Oncotarget.

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML

Jing Li, J. Taub, Tristan E. Knight, 2021, Blood Cancer Journal.

Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage

J. T. Caldwell, J. Taub, H. Edwards, 2015, Molecular oncology.

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia

G. Madlambayan, J. Taub, Tristan E. Knight, 2019, Haematologica.

CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action

S. Bai, H. Edwards, Guan Wang, 2020, Journal of cellular and molecular medicine.

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer

A. Azmi, R. Mohammad, Shuang Liu, 2017, Oncotarget.

Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells

J. Taub, Hai Lin, H. Edwards, 2017, Scientific Reports.

Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.

J. T. Caldwell, J. Taub, Wei Chen, 2015, Cancer letters.

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

J. T. Caldwell, Shengyan Xiang, X. Zhang, 2016, Clinical Cancer Research.

Polysaccharides Extracted From Panax Ginseng C.A. Mey Enhance Complement Component 4 Biosynthesis in Human Hepatocytes

Liwei Sun, Fangbing Liu, Jianzeng Liu, 2021, Frontiers in Pharmacology.

Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

J. Taub, Hai Lin, H. Edwards, 2015, Oncotarget.

Targeting PI3K, mTOR, ERK, and Bcl‐2 signaling network shows superior antileukemic activity against AML ex vivo

Shuang Liu, J. Taub, Hai Lin, 2018, Biochemical pharmacology.

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

J. Taub, Tristan E. Knight, L. Polin, 2019, Clinical Cancer Research.

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation

J. Taub, M. Hüttemann, Fangbing Liu, 2020, Cancers.

Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines.

Xuelian Xu, Yingjie Guo, Wenxiu Qi, 2011, Molecular medicine reports.

Acute Myeloid Leukemia Cells Harboring MLL Fusion Genes or with the Acute Promyelocytic Leukemia Phenotype Are Sensitive to the Bcl-2-selective Inhibitor ABT-199

J. T. Caldwell, J. Taub, Hai Lin, 2014, Leukemia.

Targeting histone deacetylases (HDACs) and Wee1 for treating high‐risk neuroblastoma

J. Taub, S. Buck, H. Edwards, 2015, Pediatric blood & cancer.

Co-targeting of HDAC, PI3K, and Bcl-2 Results in Metabolic and Transcriptional Reprogramming and Decreased Mitochondrial Function in Acute Myeloid Leukemia.

A. Dombkowski, X. Bao, J. Taub, 2022, Biochemical pharmacology.

Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.

Shuang Liu, Yiqun Jiang, Chengshi Quan, 2017, Oncology reports.

Cotargeting of Bcl-2 and Mcl-1 Shows Promising Antileukemic Activity against AML Cells Including those with Acquired Cytarabine Resistance.

Fangbing Liu, Hai Lin, Guan Wang, 2021, Experimental Hematology.

Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo

J. Taub, Liwei Sun, Tristan E. Knight, 2019, Targeted Oncology.

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer

A. Azmi, R. Mohammad, J. Taub, 2012, PloS one.

Acquired Resistance to Venetoclax plus Azacitidine in Acute Myeloid Leukemia: in vitro Models and Mechanisms.

X. Bao, J. Taub, M. Hüttemann, 2023, Biochemical pharmacology.

Immobilization of β-Cyclodextrin-Conjugated Lactoferrin onto Polymer Monolith for Enrichment of Ga in Metabolic Residues of Ga-Based Anticancer Drugs.

Q. Jia, Haijiao Zheng, Xiqian Li, 2017, Biomacromolecules.

Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.

J. T. Caldwell, J. Taub, Wei Chen, 2015, Cancer letters.

Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells.

L. Cui, Guan Wang, Y. Ge, 2014, Oncology reports.

Targeting histone deacetylases (HDACs) and Wee1 for treating high‐risk neuroblastoma

J. Taub, S. Buck, Guan Wang, 2015, Pediatric blood & cancer.

Combining the Novel FLT3 and MERTK Dual Inhibitor MRX-2843 with Venetoclax Results in Promising Antileukemic Activity Against FLT3-ITD AML

J. Taub, M. Hüttemann, Guan Wang, 2024, Leukemia Research.

Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.

J. Taub, Guan Wang, Y. Ge, 2024, Biochemical pharmacology.